{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T10:52:21Z","timestamp":1782989541563,"version":"3.54.5"},"reference-count":10,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2026.0080","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T10:13:25Z","timestamp":1782987205000},"source":"Crossref","is-referenced-by-count":0,"title":["What anticoagulants should we use to treat atrial fibrillation?"],"prefix":"10.3238","author":[{"given":"Paulus","family":"Kirchhof","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"10.3238\/arztebl.m2026.0080_ref1","doi-asserted-by":"crossref","unstructured":"Hart RG, Benavente O, McBride R, Pearce LA: Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131: 492\u2013501","DOI":"10.7326\/0003-4819-131-7-199910050-00003"},{"key":"10.3238\/arztebl.m2026.0080_ref2","doi-asserted-by":"crossref","unstructured":"Le Heuzey JY, Ammentorp B, Darius H, et al. : Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry. Thromb Haemost 2014; 111: 833\u201341","DOI":"10.1160\/TH13-12-1007"},{"key":"10.3238\/arztebl.m2026.0080_ref3","doi-asserted-by":"crossref","unstructured":"Ruff CT, Giugliano RP, Braunwald E, et al.: Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955\u201362","DOI":"10.1016\/S0140-6736(13)62343-0"},{"key":"10.3238\/arztebl.m2026.0080_ref4","doi-asserted-by":"crossref","unstructured":"Carnicelli AP, Hong H, Connolly SJ, et al.: Direct Oral Anticoagulants versus Warfarin in patients with atrial fibrillation: Patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex. Circulation 2022; 145: 242\u2013255","DOI":"10.1161\/CIR.0000000000001058"},{"key":"10.3238\/arztebl.m2026.0080_ref5","unstructured":"Engelbertz C, et al.: Direct oral anticoagulants versus phenprocoumon:\u00a0Mortality, thromboembolism and major hemorrhage. A systematic review and meta-analysis of routine data studies. Dtsch Arztebl Int 2026; 123: 377\u201384. DOI: 10.3238\/arztebl.m2026.0064."},{"key":"10.3238\/arztebl.m2026.0080_ref6","doi-asserted-by":"crossref","unstructured":"Staerk L, Fosbol EL, Lip GYH, et al.: Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study. Eur Heart J 2017; 38: 907\u2013915","DOI":"10.1093\/eurheartj\/ehw496"},{"key":"10.3238\/arztebl.m2026.0080_ref7","doi-asserted-by":"crossref","unstructured":"Lip GYH, Benamouzig R, Martin AC, Pesce G, Gusto G, Quignot N, et al.: Comparative safety and effectiveness of oral anticoagulants in key subgroups of patients with non-valvular atrial fibrillation and at high risk of gastrointestinal bleeding: A cohort study based on the French National Health Data System (SNDS). PLoS One 2025;20: e0317895","DOI":"10.1371\/journal.pone.0317895"},{"key":"10.3238\/arztebl.m2026.0080_ref8","doi-asserted-by":"crossref","unstructured":"Souverein PC, van den Ham HA, Huerta C, Merino EM, Montero D, Leon-Munoz LM, et al. Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation. Br J Clin Pharmacol 2021;87: 988\u20131000","DOI":"10.1111\/bcp.14450"},{"key":"10.3238\/arztebl.m2026.0080_ref9","doi-asserted-by":"crossref","unstructured":"Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376: 975\u201383","DOI":"10.1016\/S0140-6736(10)61194-4"},{"key":"10.3238\/arztebl.m2026.0080_ref10","doi-asserted-by":"crossref","unstructured":"Becher N, Metzner A, Toennis T, Kirchhof P, Schnabel RB: Atrial fibrillation burden: a new outcome predictor and therapeutic target. Eur Heart J 2024;45: 2824\u20132838","DOI":"10.1093\/eurheartj\/ehae373"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2026.0080","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T10:13:47Z","timestamp":1782987227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2026.0080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":10,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2026.0080","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]}}}